Point-of-care diagnostics: An advancing sector with nontechnical issues

Expert Review of Molecular Diagnostics

Volumn 8, Issue 6, 2008, Pages 679-688

  Huckle, David ^a  

^a Adams Business Associates   (United Kingdom)

Author keywords

Diagnostics; Economics; Healthcare; In vitro diagnostics; Multiplex assays; Point of care; Regulatory; Reimbursement; Segmentation; Technology

Indexed keywords

GLUCOSE;

DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE PERSONNEL; POINT OF CARE TESTING; REVIEW; SELF EVALUATION;

COMPUTERS; DISEASE; HUMANS; POINT-OF-CARE SYSTEMS; TECHNOLOGY, MEDICAL;

EID: 56049110888     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.6.679     Document Type: Review

References (32)

1. Price PP, Kricka LJ. Improving healthcare accessibility through point of-care technologies Clin. Chem. 53(9), 1665-1675 (2007). • Useful in understanding the basic technical and political challenges that point-of-care (PoC) testing has faced.
2. Huckle D. Point-of-care diagnostics: will the hurdles be overcome this time? Expert Rev. Med. Devices 3(4), 421-426 (2006). • Useful in understanding the basic technical and political challenges that PoC testing has faced.
3. Nichols JH. Point-of-care Testing, Chapter 50. In: The Immunoassay Handbook (2nd Edition). Wild D (Ed.). Nature Publishing Group, London, UK (2005). • Useful in understanding the basic technical and political challenges that PoC testing has faced.
4. Brown JB, Harris SB, Webster-Bogaert S, Porter S. Point-of-care testing in diabetes management: what role does it play? Diabetes Spectr. 17, 244-248 (2004).
5. Hamilton AJ, Swales LA, Neill J et al. Risk stratification of chest pain patients in the emergency department by a nurse utilizing a point of care protocol. Eur. J. Emerg. Med. 15, 9-15 (2008).
6. Groves M. Point of care testing. IVD Technology 11(3), 68 (2005). • Interesting analysis of the economic arguments for PoC versus central laboratory testing.
7. Clinical Aspects of Iodine Metabolism. Wayne E, Koutras DA, Alexander WD (Eds). Blackwell Scientific Publications, Oxford, UK. 303 (1964). • Important for understanding the development and evolution of modern IVD tests and the drive for laboratory testing.
8. Man EB, Kydd DM, Peters JP. Butanol extractable iodine of serum. J. Clin. Invest. 30, 531-538 (1951). • Important for understanding the development and evolution of modern IVD tests and the drive for laboratory testing.
9. Berson SA, Yalow RS, Bauman A, Rothschild MA, Newerly K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35(2), 170-90 (1956). • First article to document binding assays, which over time became immunoassays.
10. Glover JS & staff. Amersham International Product Literature (1968). • Of historical interest.
11. Ekins RP. An overview of present and future ultrasensitive non-isotopic immunoassay development. Clin. Biochem. Rev. 8, 12-23 (1987). • Marked the time of real growth of immunoassays.
12. Malchoff CD, Shoukri K, Landau JI, Buchert JM. A novel non-invasive blood glucose monitor. Diabetes Care 25(12), 2268-2275 (2002) •• Very important article as an example and indicator of the ultimate direction of PoC testing - to eliminate the use of samples.
13. Webster S. What is the point of Point of Care? Eur. Clin. Lab. 25(5), 10-11 (2006).
14. Fitzgibbon F, Brown A, Meenan BJ. Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis point of care. Conf. Proc. IEEE Eng. Med. Biol. Soc. 7(2), 1762-1765 (2007).
15. Gardiner C, Williams K, Mackie IJ. et al. Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. Br. J. Haematol. 128, 241-247 (2004). • Important as an example of current PoC trends in areas other than glucose testing.
16. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31(3), 596-615 (2008). •• Very important economic analysis for PoC testing.
17. Evidence-Based Laboratory Medicine: Principles, Practice and Outcomes (2nd Edition). Price CP, Christenson RH (Eds). Washington AACC Press, DC, USA (2007). •• Very important economic analysis for PoC testing.
18. Petricoin EF, Llotta LA. A revolutionary approach to biomarker discovery. The Scientist 20(11), 32 (2006).
19. The Emerging European Molecular POC Testing Markets. Market Research Report. Frost & Sullivan Communications, CA, USA. April (2008).
20. Burrill GS. Life Sciences: A Changing Prescription, Diagnostics. Burrill & Company, CA, USA, p 90 (2006).
21. Sorensen M. PoC testing, new monitoring strategies on fast growth paths in European healthcare arenas. Biomedical Business & Technology 30(1), 1 (2007). • Important for North American readers as another view on how PoC testing will develop in the European market.
22. Point-Of-Care Testing: Perceptions And Reality. Study conducted for The Science Advisory Board. Bioinformatics Inc. (1998). • Of interest for user views in the early phase of PoC testing.
23. Reder A. Regulating the point of care: the IVD connectivity industry consortium. Medical Device & Diagnostic Industry 23(4), 63-73 (2001).
24. Rainey PM. Outcomes assessment for point of care testing. Clin. Chem. 44, 1595-1596 (1998).
25. Plant B, Developing point of care A1c tests for diabetes monitoring. IVD Technology 14(6), 51 (2008).
26. Pearson J. Point-of-care testing and clinical governance. Clin. Chem. Lab. Med. 44(6), 765-767 (2006).
27. Christel MD. R&D Spending will grow as industry pressures continue, MedAdNews 27 (1), 1 (2008).
28. Market review of the global diagnostics market, October 2007. www.diagnox.co.uk
29. Centre for evidence based purchasing, NHS purchasing and supply agency (PASA) Evaluation report. Three point of care devices for troponin measurement (PASA Website). May 2006. www.pasa.nhs.uk/pasa/Doc. aspx?Path=[MN][SP]/ NHSprocurement/CEP/poc/Report%2006020.pdf
30. BodyTel Scientific Inc. Press Release & Product Literature, Medica Exhibition, Dusseldorf, Germany 2007. www.bodytel.com
31. Charny M. Reimbursement for point-of-care diagnostics opportunities and barriers. Market Access for Point-of-Care Diagnostics Conference, Amsterdam, 13-14 May 2008. www.informa-ls.com/POCT/docs
32. Price CP, Kricka LJ. Point-of-Care testing: systems reengineering of healthcare provision to reduce errors and improve outcomes (2007). www.bloodgas.org